Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 12.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 12,665 shares of the company’s stock after selling 1,795 shares during the period. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $283,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 5.5% in the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock valued at $259,514,000 after purchasing an additional 606,507 shares during the period. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares during the period. Federated Hermes Inc. lifted its stake in shares of Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after purchasing an additional 98,865 shares during the period. Finally, Chevy Chase Trust Holdings LLC lifted its stake in shares of Intellia Therapeutics by 8.4% in the first quarter. Chevy Chase Trust Holdings LLC now owns 1,074,610 shares of the company’s stock valued at $29,563,000 after purchasing an additional 83,435 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on NTLA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 24th. Royal Bank of Canada cut their target price on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Truist Financial restated a “buy” rating and set a $120.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. cut their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, Stifel Nicolaus cut their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.

Intellia Therapeutics Trading Down 0.1 %

NASDAQ NTLA opened at $22.52 on Thursday. The company’s fifty day simple moving average is $23.38 and its 200-day simple moving average is $24.24. Intellia Therapeutics, Inc. has a 52 week low of $19.21 and a 52 week high of $34.94. The stock has a market cap of $2.17 billion, a P/E ratio of -4.20 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. The company’s quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.40) earnings per share. On average, research analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.